Conjugated monoclonal antibodies (mAbs) are a type of targeted cancer therapy that combines monoclonal antibodies with a cytotoxic agent, such as a drug or a radioactive substance. These agents are designed to specifically target and kill cancer cells while sparing normal cells. The monoclonal antibody acts as a delivery vehicle, homing in on cancer cells that express a particular antigen, and the attached cytotoxic agent executes the cell-killing function.
